Compare PTCT & UEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | UEC |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.8B |
| IPO Year | 2006 | 2008 |
| Metric | PTCT | UEC |
|---|---|---|
| Price | $71.41 | $11.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | ★ $80.65 | $18.95 |
| AVG Volume (30 Days) | 794.0K | ★ 7.9M |
| Earning Date | 05-07-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $264,734,000.00 | $66,837,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.70 | $220.11 |
| P/E Ratio | $79.77 | ★ N/A |
| Revenue Growth | 36.19 | ★ 29737.95 |
| 52 Week Low | $57.08 | $8.91 |
| 52 Week High | $90.87 | $20.34 |
| Indicator | PTCT | UEC |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 49.92 |
| Support Level | $67.57 | $10.41 |
| Resistance Level | $73.86 | $12.41 |
| Average True Range (ATR) | 2.00 | 0.68 |
| MACD | 0.17 | -0.10 |
| Stochastic Oscillator | 54.41 | 32.04 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.